Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference

Core Insights - Revolution Medicines, Inc. is a late-stage clinical oncology company focused on developing targeted therapies for RAS-addicted cancers [3] Group 1: Corporate Presentation - Mark A. Goldsmith, M.D., Ph.D., CEO and Chairman of Revolution Medicines, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 10:30 a.m. PT [1] Group 2: R&D Pipeline - The company's R&D pipeline includes RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins, with key candidates being daraxonrasib (RMC-6236), elironrasib (RMC-6291), zoldonrasib (RMC-9805), and RMC-5127, all currently in clinical development [3] - Additional development opportunities focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C) [3]